AbbVie Inc. ("AbbVie") (NYSE /
CHX / Euronext Paris / SIX: ABBV) today informs its stockholders that it has
filed an amendment to its tender offer statement on Schedule TO and a Current
Report on Form 8-K with the U.S. Securities and Exchange Commission ("SEC")
relating to its previously announced agreement and plan of reorganization with
Pharmacyclics, Inc.
AbbVie makes available free of charge on its website, its Annual Report on Form
10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, reports filed
pursuant to Section 16 of the U.S. Securities Exchange Act of 1934 and
amendments to those reports filed with or furnished to the SEC as soon as
reasonably practicable after AbbVie electronically files these documents with,
or furnishes them to, the SEC. These documents are posted on AbbVie's website
at www.abbvieinvestor.com.
The SEC maintains a website that contains reports, proxy statements and other
information regarding issuers that file electronically with the SEC. These
materials may be obtained electronically by accessing the SEC's home page at
http://www.sec.gov.
Copies of the above referenced information will also be made available, free of
charge, upon written request to AbbVie Inc., Investor Relations, 1 North
Waukegan Road, North Chicago, Illinois 60064, U.S.A.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: NewsPress Releases
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in